Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Refinement of prognosis and th...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

Bibliographic Details
Main Authors: Konstantinos Liapis, Vasileios Papadopoulos, George Vrachiolias, Athanasios G. Galanopoulos, Menelaos Papoutselis, Sotirios G. Papageorgiou, Panagiotis T. Diamantopoulos, Vassiliki Pappa, Nora-Athina Viniou, Alexandra Kourakli, Dimitris Τsokanas, Theodoros P. Vassilakopoulos, Eleftheria Hatzimichael, Eleni Bouronikou, Maria Ximeri, Charalambos Pontikoglou, Aekaterini Megalakaki, Panagiotis Zikos, Panayiotis Panayiotidis, Maria Dimou, Stamatis Karakatsanis, Maria Papaioannou, Anna Vardi, Flora Kontopidou, Nikolaos Harchalakis, Ioannis Adamopoulos, Argiris Symeonidis, Ioannis Kotsianidis
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00424-4
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1038/s41408-021-00424-4

Similar Items

  • Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
    by: Konstantinos Liapis, et al.
    Published: (2020-07-01)
  • The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
    by: Panagiotis Diamantopoulos, et al.
    Published: (2019-05-01)
  • Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
    by: Sotirios G. Papageorgiou, et al.
    Published: (2020-12-01)
  • Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes
    by: Ioannis Mitroulis, et al.
    Published: (2023-05-01)
  • Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
    by: Panagiotis T. Diamantopoulos, et al.
    Published: (2022-10-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs